Hemispherx Biopharma Management Team: Reflects Company’s Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder Value
February 22, 2016 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) has announced that the Board of Directors has made several changes to its...
Hemispherx Presents New Data on Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus
January 21, 2014 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 21, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB), today announced that Dr. William M. Mitchell of Vanderbilt University will present a research paper on January 21,...